Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap

RNA

Volumn 11, Issue 8, 2005, Pages 1238-1244

  Yan, Yifei ^a   Svitkin, Yuri ^a   Lee, Joseph M ^a   Bisaillon, Martin ^c   Pelletier, Jerry ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

7 methyl guanosine; Cap analog; Ribavirin; RTP; Translation

Indexed keywords

7 METHYLGUANOSINE; CAP BINDING PROTEIN; MESSENGER RNA; RIBAVIRIN;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CHROMATOGRAPHY; CROSS LINKING; MOLECULAR INTERACTION; PRIORITY JOURNAL; RNA CAPPING;

EID: 23644440980     PISSN: 13558382     EISSN: 14699001     Source Type: Journal    
DOI: 10.1261/rna.2930805     Document Type: Article

References (45)

1. Adams, B.L., Morgan, M., Muthukrishnan, S., Hecht, S.M., and Shatkin, A.J. 1978. The effect of "cap" analogs on reovirus mRNA binding to wheat germribosomes. Evidence for enhancement of ribosomal binding via a preferred cap conformation. J. Biol. Chem. 253: 2589-2595.
2. Bougie, I. and Bisaillon, M. 2004. The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme. J. Biol. Chem. 279: 22124-22130.
3. Cai, A., Jankowska-Anyszka, M., Centers, A., Chlebicka, L., Stepinski, J., Stolarski, R., Darzynkiewicz, E., and Rhoads, R.E. 1999. Quantitative assessment of mRNA cap analogues as inhibitors of in vitro translation. Biochemistry 38: 8538-8547.
4. Crotty, S., Maag, D., Arnold, J.J., Zhong, W., Lau, J.Y., Hong, Z., Andino, R., and Cameron, C.E. 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6: 1375-1379.
5. Crotty, S., Cameron, C.E., and Andino, R. 2001. RNA virus error catastrophe: Direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. 98: 6895-6900.
6. Darzynkiewicz, E., Antosiewicz, J., Ekiel, I., Morgan, M.A., Tahara, S.M., and Shatkin, A.J. 1981. Methyl esterification of m7G5′p reversibly blocks its activity as an analog of eukaryotic mRNA 5′-caps. J. Mol. Biol. 153: 451-458.
7. Darzynkiewicz, E., Ekiel, I., Tahara, S.M., Seliger, L.S., and Shatkin, A.J. 1985. Chemical synthesis and characterization of 7-methylguanosine cap analogues. Biochemistry 24: 1701-1707.
8. Darzynkiewicz, E., Ekiel, I., Lassota, P., and Tahara, S.M. 1987. Inhibition of eukaryotic translation by analogues of messenger RNA 5′-cap: Chemical and biological consequences of 5′-phosphate modifications of 7-methylguanosine 5′-monophosphate. Biochemistry 26: 4372-4380.
9. Darzynkiewicz, E., Stepinski, J., Ekiel, I., Goyer, C., Sonenberg, N., Temeriusz, A., Jin, Y., Sijuwade, T., Haber, D., and Tahara, S.M. 1989. Inhibition of eukaryotic translation by nucleoside 5′-monophosphate analogues of mRNA 5′-cap: changes in N7 substituent affect analogue activity. Biochemistry 28: 4771-4778.
10. De Clercq, E. 1993. Antiviral agents: Characteristic activity spectrum depending on the molecular target with which they interact. Adv. Virus Res. 42: 1-55.
11. Dyer, B.W., Ferrer, F.A., Klinedinst, D.K., and Rodriguez, R. 2000. A noncommercial dual luciferase enzyme assay system for reporter gene analysis. Anal. Biochem. 282: 158-161.
12. Edery, I., Altmann, M., and Sonenberg, N. 1988. High-level synthesis in Escherichia coli of functional cap-binding eukaryotic initiation factor eIF-4E and affinity purification using a simplified capanalog resin. Gene 74: 517-525.
13. Edery, I., Chu, L.L., Sonenberg, N., and Pelletier, J. 1995. An efficient strategy to isolate full-length cDNAs based on an mRNA cap retention procedure (CAPture). Mol. Cell. Biol. 15: 3363-3371.
14. Furuichi, Y., Morgan, M.A., and Shatkin, A.J. 1979. Synthesis and translation of mRNA containing 5′-terminal 7-ethylguanosine cap. J. Biol. Chem. 254: 6732-6738.
15. Gingras, A.C., Raught, B., and Sonenberg, N. 1999. eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem. 68: 913-963.
16. _. 2001. Regulation of translation initiation by FRAP/mTOR. Genes & Dev. 15: 807-826.
17. Goswami, B.B., Borek, E., Sharma, O.K., Fujitaki, J., and Smith, R.A. 1979. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 89: 830-836.
18. Grifo, J.A., Tahara, S.M., Morgan, M.A., Shatkin, A.J., and Merrick, W.C. 1983. New initiation factor activity required for globin mRNA translation. J. Biol. Chem. 258: 5804-5810.
19. Hickey, E.D., Weber, L.A., Baglioni, C., Kim, C.H., and Sarma, R.H. 1977. A relation between inhibition of protein synthesis and conformation of 5′-phosphorylated 7-methylguanosine derivatives. J. Mol. Biol. 109: 173-183.
20. Ishida, T., Doi, M., Ueda, H., Inoue, M., and Sheldrick, G.M. 1988. Specific ring stacking interaction on the tryptophan-7-methylguanine system: Comparative crystallographic studies of indole derivatives-7-methylguanine base, nucleoside, nucleotide complexes. J. Am. Chem. Soc. 110: 2286-2294.
21. Kentsis, A., Topisirovic, I., Culjkovic, B., Shao, L., and Borden, K.L. 2004. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc. Natl. Acad. Sci. 101: 18105-18110.
22. Lazaris-Karatzas, A., Montine, K.S., and Sonenberg, N. 1990. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345: 544-547.
23. Maag, D., Castro, C., Hong, Z., and Cameron, C.E. 2001. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 276: 46094-46098.
24. Marcotrigiano, J., Gingras, A.C., Sonenberg, N., and Burley, S.K. 1997. Cocrystal structure of the messenger RNA 5′ cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell 89: 951-961.
25. Matsuo, H., Li, H., McGuire, A.M., Fletcher, C.M., Gingras, A.C., Sonenberg, N., and Wagner, G. 1997. Structure of translation factor eIF4E bound to m7GDP and interaction with 4E-binding protein. Nat. Struct. Biol. 4: 717-724.
26. Miller, J.P., Kigwana, L.J., Streeter, D.G., Robins, R.K., Simon, L.N., and Roboz, J. 1977. The relationship between the metabolism of ribavirin and its proposed mechanism of action. Ann. NY Acad. Sci. 284: 211-229.
27. Muller, W.E., Maidhof, A., Taschner, H., and Zahn, R.K. 1977. Virazole (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; a cytostatic agent. Biochem. Pharmacol. 26: 1071-1075.
28. Niedzwiecka, A., Darzynkiewicz, E., and Stolarski, R. 2004. Thermodynamics of mRNA 5′ cap binding by eukaryotic translation initiation factor eIF4E. Biochemistry 43: 13305-13317.
29. Novac, O., Guenier, A.S., and Pelletier, J. 2004. Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen. Nucleic Acids Res. 32: 902-915.
30. Page, T. and Connor, J.D. 1990. The metabolism of ribavirin in erythrocytes and nucleated cells. Int. J. Biochem. 22: 379-383.
31. Pelletier, J. and Sonenberg, N. 1985. Photochemical cross-linking of cap binding proteins to eucaryotic mRNAs: Effect of mRNA 5′ secondary structure. Mol. Cell. Biol. 5: 3222-3230.
32. Ruggero, D., Montanaro, L., Ma, L., Xu, W., Londei, P., Cordon-Cardo, C., and Pandolfi, P.P. 2004. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10: 484-486.
33. Sambrook, J. and Russell, D.W. 2001. Molecular cloning. A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
34. Sidwell, R.W., Huffman, J.H., Khare, G.P., Allen, L.B., Witkowski, J.T., and Robins, R.K. 1972. Broad-spectrum antiviral activity of virazole: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177: 705-706.
35. Sidwell, R.W., Robins, R.K., and Hillyard, I.W. 1979. Ribavirin: An antiviral agent. Pharmacol. Ther. 6: 123-146.
36. Sonenberg, N. 1981. ATP/Mg++-dependent cross-linking of cap binding proteins to the 5′ end of eukaryotic mRNA. Nucleic Acids Res. 9: 1643-1656.
37. Sonenberg, N. and Shatkin, A.J. 1977. Reovirus mRNA can be covalently crosslinked via the 5′ cap to proteins in initiation complexes. Proc. Natl. Acad. Sci. 74: 4288-4292.
38. _. 1978. Nonspecific effect of m7GMP on protein-RNA interactions. J. Biol. Chem. 253: 6630-6632.
39. Sonenberg, N., Morgan, M.A., Merrick, W.C., and Shatkin, A.J. 1978. A polypeptide in eukaryotic initiation factors that crosslinks specifically to the 5′-terminal cap in mRNA. Proc. Natl. Acad. Sci. 75: 4843-4847.
40. Streeter, D.G., Witkowski, J.T., Khare, G.P., Sidwell, R.W., Bauer, R.J., Robins, R.K., and Simon, L.N. 1973. Mechanism of action of 1-β- Dribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broadspectrum antiviral agent. Proc. Natl. Acad. Sci. 70: 1174-1178.
41. Svitkin, Y.V. and Sonenberg, N. 2003. Cell-free synthesis of encephalomyocarditis virus. J. Virol. 77: 6551-6555.
42. _. 2004. An efficient system for cap- and poly(A)-dependent translation in vitro. Methods Mol. Biol. 257: 155-170.
43. Tahara, S.M., Morgan, M.A., and Shatkin, A.J. 1983. Binding of inosine-substituted mRNA to reticulocyte ribosomes and eukaryotic initiation factors 4A and 4B requires ATP. J. Biol. Chem. 258: 11350-11353.
44. Tam,R.C., Lau, J.Y., andHong,Z. 2001.Mechanisms of action of ribavirin in antiviral therapies. Antivir. Chem. Chemother. 12: 261-272.
45. Wendel, H.-G., de Stanchina, E., Fridman, J.S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., and Lowe, S.W. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337.